Adamas Pharmaceuticals Inc (ADMS) Receives Average Recommendation of “Buy” from Brokerages

Shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) have earned a consensus rating of “Buy” from the twelve analysts that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $45.67.

A number of research firms recently weighed in on ADMS. Mizuho restated a “buy” rating and set a $48.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, January 23rd. BidaskClub upgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, January 25th. ValuEngine upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Wednesday, January 3rd. Finally, Cowen set a $55.00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, December 13th.

Hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its stake in Adamas Pharmaceuticals by 13,028.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after purchasing an additional 135,235 shares in the last quarter. Hikari Power Ltd purchased a new stake in Adamas Pharmaceuticals in the 3rd quarter worth $635,000. EAM Investors LLC purchased a new stake in Adamas Pharmaceuticals in the 3rd quarter worth $1,795,000. Vanguard Group Inc. lifted its stake in Adamas Pharmaceuticals by 4.0% in the 2nd quarter. Vanguard Group Inc. now owns 745,237 shares of the specialty pharmaceutical company’s stock worth $13,034,000 after purchasing an additional 28,818 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Adamas Pharmaceuticals by 9.1% in the 2nd quarter. State Street Corp now owns 285,359 shares of the specialty pharmaceutical company’s stock worth $4,990,000 after buying an additional 23,708 shares during the last quarter. Institutional investors and hedge funds own 68.76% of the company’s stock.

Adamas Pharmaceuticals (ADMS) traded up $0.05 on Tuesday, hitting $33.86. 511,676 shares of the company were exchanged, compared to its average volume of 879,626. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.32 and a current ratio of 8.35. Adamas Pharmaceuticals has a 52 week low of $13.50 and a 52 week high of $44.00. The stock has a market cap of $869.47, a PE ratio of -10.06 and a beta of 1.17.

WARNING: “Adamas Pharmaceuticals Inc (ADMS) Receives Average Recommendation of “Buy” from Brokerages” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/13/adamas-pharmaceuticals-inc-adms-receives-average-recommendation-of-buy-from-brokerages.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply